GlassScriptPhysician profile
Alison Welch
NPI 1194542605
$1,257.09
in general payments reported to CMS, 2019-2025
18 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $479.92 | 2025 | Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $129.96 | 2025 | |
| Abbott Laboratories | $125.03 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $77.60 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $63.09 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.85 | 2025 | Xifaxan |
| Abbvie INC. | $56.05 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $46.56 | 2025 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $31.52 | 2025 | |
| Boston Scientific Corporation | $30.97 | 2025 | General - Pain Management |
| Pfizer INC. | $27.72 | 2025 | |
| Dexcom, INC. | $23.58 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.22 | 2025 | Jardiance |
| Lundbeck LLC | $20.71 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.57 | 2025 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.82 | 2025 | Trelegy Ellipta |
| Amgen INC. | $15.57 | 2025 | Repatha |
| Exact Sciences Corporation | $14.35 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.